Company Description
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis.
Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist.
The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands.
In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss.
The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions.
Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
| Country | United States |
| Founded | 1923 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 10,000 |
| CEO | Joseph Morrissey |
Contact Details
Address: 30 Hudson Street, Floor 33 Jersey City, New Jersey 07302 United States | |
| Phone | 551 430 6900 |
| Website | organon.com |
Stock Details
| Ticker Symbol | OGN |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1821825 |
| CUSIP Number | 68622V106 |
| ISIN Number | US68622V1061 |
| Employer ID | 46-4838035 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph T. Morrissey Jr. | Interim Chief Executive Officer |
| Carrie Smith Cox | Executive Chair of the Board |
| Matthew M. Walsh C.F.A. | Executive Vice President and Chief Financial Officer |
| Dr. Juan Camilo Arjona Ferreira M.D. | Executive Vice President, Head of Research and Development and Chief Medical Officer |
| Juliana Papa Drinane | Interim Head of Manufacturing and Supply |
| Nico Van Hoecke | Head of International Commercial |
| Mike Casia | Interim Head of U.S. Commercial and Government Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | 8-K | Current Report |
| Apr 24, 2026 | ARS | Filing |
| Apr 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Feb 24, 2026 | 10-K | Annual Report |